Sell Dr Reddys; target of Rs 1150: Emkay Global Financial

sell

Emkay Global Financial's research report on Dr Reddys

Adjusted for the milestone payment received from Journey Medical Corp, 3QFY25 EBITDA for Dr Reddy’s was below street/our estimates. The PAT miss was higher on account of lower other income. The sharp 160bps QoQ decline in gross margin validates the concern we had raised post-2Q that gross margin could have begun its descent, and reinforces our view that EBITDA margin will revert to pre-gRevlimid levels (~21%) by FY27E. The gRevlimid-driven miss in US sales (a meaningful miss nevertheless), the management’s acknowledgement of incremental pricing pressures in top products in the US, the receipt of a CRL for iron sucrose, and limited clarity offered on the CY26 Semaglutide opportunity were clear negatives.

Outlook

We broadly maintain our lowerthan-street earnings estimates. We retain SELL and Dec-25E TP of Rs1,150.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Dr Reddys - 24012025 - emkay